breast cancer

Ly D, Hoyt AC, Weimer A, Chang EH, Capiro N, Xie C, Chow L. Breast Cancer Among Transgender and Nonbinary Patients: Paradigms for Improving Data[...]

Katz S, Ciuba D, Ribas A, Shelach N, Zelinger G, Barrow B, Corn BW. A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women[...]

Hanalis-Miller T, Ricon-Becker I, Sakis N, Trachtenberg E, Ohayon F, Wadhawker S, Birnboim Y, Magen A, Sharon E, Tarrasch R, Goldzweig G, Cole SW, Jacoby[...]

Hamid A, Fonarow GC, Butler J, Hall ME. How do breast cancer clinical trials approach cardiovascular safety: targeted or generalized? Cardiooncology. 2024 Feb 7;10(1):6. doi:[...]

Glaspy J, Bondarenko I, Krasnozhon D, Rutty D, Chen J, Fu Y, Wang S, Hou Q, Li S. Efbemalenograstim alfa not inferior to pegfilgrastim in[...]

Glaspy J, Bondarenko I, Burdaeva O, Chen J, Rutty D, Li R, Wang S, Hou Q, Li S. Efbemalenograstim alfa, an Fc fusion protein, long-acting[...]

Ji J, Bae M, Sun CL, Wildes TM, Freedman RA, Magnuson A, O'Connor T, Moy B, Klepin HD, Chapman AE, Tew WP, Dotan E, Fenton[...]

Singh M, Paul MK, Roy S. Editorial: Pharmaceutically targeting hypoxia in the breast cancer microenvironment: mechanistic and translational approaches. Front Oncol. 2023 Aug 23;13:1265523. doi:[...]

Zhang J, McAndrew NP, Wang X, Du Y, DiCarlo B, Wang M, Chen K, Yu W, Hu X. Preclinical and clinical activity of DZD1516, a[...]

Khallouki F, Hajji L, Saber S, Bouddine T, Edderkaoui M, Bourhia M, Mir N, Lim A, El Midaoui A, Giesy JP, Aboul-Soud MAM, Silvente-Poirot S,[...]